Drugs / Pamrevlumab
Trials 20 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01181245 | Dec 2008 → May 2014 | — | Kyntra Bio | Completed | No outcome recorded |
| Phase 1 | NCT00782561 | Apr 2008 → Jun 2009 | focal segmental glomerulosclerosis | Kyntra Bio | Terminated | No outcome recorded |
| Phase 1 | NCT00754143 | Mar 2008 → Dec 2009 | diabetes mellitus, diabetic kidney disease | Kyntra Bio | Completed | No outcome recorded |
| Phase 1 | NCT00102297 | Jan 2005 → Jun 2007 | diabetes mellitus | Kyntra Bio | Completed | No outcome recorded |
| Phase 1 | NCT00074698 | Dec 2003 → May 2004 | idiopathic pulmonary fibrosis | Kyntra Bio | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02210559 | Jul 2014 → Dec 2021 | pancreatic neoplasm | Kyntra Bio | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT04432298 | Jun 2020 → Mar 2021 | COVID-19 | Kyntra Bio | Terminated | No outcome recorded |
| Phase 2 | NCT02606136 | Jan 2016 → May 2020 | Duchenne muscular dystrophy | Kyntra Bio | Terminated | No outcome recorded |
| Phase 2 | NCT01890265 | Jul 2013 → Nov 2017 | idiopathic pulmonary fibrosis | Kyntra Bio | Completed | No outcome recorded |
| Phase 2 | NCT01262001 | Mar 2011 → Jun 2014 | idiopathic pulmonary fibrosis | Kyntra Bio | Completed | No outcome recorded |
| Phase 2 | NCT01217632 | Aug 2010 → Jun 2015 | fibrotic liver disease | Kyntra Bio | Terminated | No outcome recorded |
| Phase 2 | NCT00913393 | Feb 2009 → Jun 2010 | diabetic kidney disease, type 2 diabetes mellitus | Kyntra Bio | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05262309 | May 2020 → Jan 2022 | COVID-19, pneumonia | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT04632940 | Mar 2021 → Jun 2023 | Duchenne muscular dystrophy | Kyntra Bio | Terminated | No outcome recorded |
| Phase 3 | NCT04419558 | Sep 2020 → Sep 2023 | idiopathic pulmonary fibrosis | Kyntra Bio | Terminated | No outcome recorded |
| Phase 3 | NCT04371666 | Aug 2020 → Feb 2023 | Duchenne muscular dystrophy | Kyntra Bio | Terminated | No outcome recorded |
| Phase 3 | NCT04229004 | Jan 2020 → Feb 2025 | pancreatic adenocarcinoma | Pancreatic Cancer Action Network | Completed | No outcome recorded |
| Phase 3 | NCT03955146 | Jun 2019 → Mar 2023 | idiopathic pulmonary fibrosis | Kyntra Bio | Terminated | No outcome recorded |
| Phase 3 | NCT03941093 | May 2019 → Jun 2024 | malignant pancreatic neoplasm | Kyntra Bio | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02851381 | Aug → Sep 2016 | malignant pancreatic neoplasm | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pamrevlumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03941093 ↗ |
| Known as | FG-3019 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02210559 ↗ |
| Action | Inhibit | “binds to and inhibits connective tissue growth factor activity.” PMID 40355288 ↗ May 2025 |
| Modality | Monoclonal antibody | “FG-3019 is a fully human monoclonal antibody that interferes with the action of connective tissue growth factor, a central mediator in the pathogenesis of fibrosis.” PMID 26965296 ↗ Mar 2016 |
| Route | Intravenous | “single intravenous (IV) infusion of FG-3019 low dose on Day 0.” NCT00074698 ↗ |
| Target | CTGF | “a fully recombinant human monoclonal antibody against CTGF” PMID 31575509 ↗ Sep 2019 |